MediWound Ltd. (NASDAQ:MDWD) Given Average Recommendation of "Moderate Buy" by Analysts

MediWound Ltd. (NASDAQ:MDWD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $32.25.

Several equities analysts recently issued reports on the company. Wall Street Zen lowered MediWound from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Weiss Ratings restated a "sell (d-)" rating on shares of MediWound in a research report on Wednesday. Finally, Zacks Research lowered MediWound from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th.

MediWound Price Performance

MDWD opened at $17.90 on Friday. The stock's 50 day simple moving average is $17.60 and its 200 day simple moving average is $18.46. MediWound has a 1 year low of $14.14 and a 1 year high of $22.50. The firm has a market cap of $198.51 million, a price-to-earnings ratio of -6.78 and a beta of 0.27.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.68). MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.The company had revenue of $5.71 million for the quarter, compared to the consensus estimate of $5.68 million. As a group, sell-side analysts anticipate that MediWound will post -2.66 EPS for the current year.

Institutional Investors Weigh In On MediWound

A number of large investors have recently made changes to their positions in the business. Rhumbline Advisers grew its position in shares of MediWound by 4.4% in the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company's stock worth $176,000 after buying an additional 481 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 649 shares during the last quarter. Corebridge Financial Inc. grew its position in shares of MediWound by 17.1% in the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 665 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 999 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of MediWound by 1,507.1% in the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,703 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.